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Myofibroblasts and their relationship with oral squamous cell 
carcinoma
Abstract
Priscilla Suassuna Carneiro Lúcio1, Alessandro Leite Cavalcanti2, Pollianna Muniz Alves3, 
Gustavo Pina Godoy2, Cassiano Francisco Weege Nonaka2
Myofibroblasts are hybrid-phenotype differentiated cells in between fibroblasts and smooth muscle 
cells. Due to their contractile features and ability to synthesize extracellular matrix components, 
cytokines, proteases, and proangiogenic factors, myofibroblasts have been implicated in the 
pathogenesis of fibrocontractive diseases and in the progression of many tumors, including oral 
squamous cell carcinoma (SCC).
Objective: To perform a literature review on the origin of myofibroblasts, their main morpho-
physiological and immunohistochemical aspects, and to discuss the correlations with oral SCC.
Method: A search was made on the PUBMED database to select the main papers in the literature in 
English related to the subject, published between January 1991 and December 2011.
Conclusion: Myofibroblasts are an important component of the stroma of oral SCCs, although they 
are not present in all tumors. Abundant presence of myofibroblasts may be associated with local 
disease recurrence and decreased patient survival. However, given the relatively limited number 
of studies on the subject, further research is needed to clarify the molecular mechanisms by which 
myofibroblasts influence the biological behavior of oral SCC.
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INTRODUCTION
Neoplasms are made of tumor cells wrapped in a 
stroma constituted by blood vessels, fibroblasts, extracellular 
matrix (ECM), inflammatory cells and, occasionally, 
myofibroblasts1-4. Even though the stroma has been 
considered for a long time as a support tissue to neoplastic 
cells, recent evidence indicates that it has a role in promoting 
malignant phenotypes2,4,5. Stromal alterations are frequently 
seen in many types of neoplasms, including oral squamous 
cell carcinoma (SCC)6.
Myofibroblasts were originally thought to be 
variants of fibroblasts present in the granulation response 
of the wound healing process, due to their contractile 
activity. Today, myofibroblasts are considered to be 
hybrid phenotype cells with fibroblast and smooth 
muscle tissue characteristics, capable of expressing 
α-smooth muscle actin (α-SMA), and characterized by 
intense synthesis of ECM proteins, growth factors - such 
as hepatocyte growth factor (HGF), platelet-derived 
growth factor (PDGF), and keratinocyte growth factor 
(KGF) - and proteases1,2,7,8.
Recent studies have shown that poorer prognosis 
in some tumor types is correlated with the presence of 
myofibroblasts in a neoplastic stroma2,5,9. An accepted 
explanation for such event is the ability of the products 
synthesized by these cells to modulate a number of 
biological events associated with malignancy, such as 
growth, differentiation, adhesion, migration, and tumor 
cell invasion1,4,6,10,11.
Additionally, studies have indicated that 
myofibroblasts may be potential targets in the treatment 
of malignant disease12-14. Among the main advantages 
related to targeting myofibroblasts in cancer treatment 
is the increased genetic stability of these cells and their 
wide applicability in different tumor types14. Strategies 
suggested to prevent strong interaction between 
myofibroblasts and malignant neoplastic cells include 
the inhibition of the signaling pathways involved in 
myofibroblast recruitment and differentiation and direct 
eradication of this cell type12,13.
Objective
This literature review aimed to look into the origin 
of myofibroblasts, their main morpho-physiological 
and immunohistochemical aspects, and to discuss the 
correlation between myofibroblasts and oral SCC.
METHOD
A search was made on database PUBMED using 
the following keywords based on the Medical Subject 
Headings (MeSH): myofibroblasts, oral squamous cell 
carcinoma and immunohistochemistry. Papers meeting 
the following criteria were included: a) data reported 
on myofibroblasts, their morpho-physiological and 
immunohistochemical aspects, and/or correlations 
between myofibroblasts and development/progression 
of oral SCC; b) study included in vivo or in vitro 
model; c) papers published between January 1991 and 
December 2011. Forty-three papers met the criteria and 
were selected for analysis.
LITERATURE REVIEW
Origin
The replacement or expansion of myofibroblasts, 
during homeostasis or disease, was originally believed 
to occur solely at the cost of the cell populations 
residing in the tissues, fibroblasts more particularly15-17. 
However, depending on the nature of the tissue and 
other characteristics of the microenvironment, several 
cell types may act as myofibroblast precursors, such as 
smooth muscle cells, pericytes18,19, endothelial cells15, 
pancreatic and hepatic stellate cells4,15, adipocytes, 
and myoepithelial cells4. Studies have also shown 
other potential sources of myofibroblasts, including 
mesenchymal stem cells residing in the tissues, bone 
marrow-derived fibrocytes, and epithelial-mesenchymal 
transition15-17,19,20.
The differentiation of fibroblasts residing in 
myofibroblasts is induced by paracrine signaling 
triggered by tissue repair or inflammation. Members 
of the transforming growth factor β (TGF-β) 
family - PDGF, insulin-like growth factor II (IGF-II), 
and interleukin-4 (IL-4) - seem to be the main factor 
involved in the differentiation process of fibroblasts into 
myofibroblasts1,2,12. Special attention is given to TGF-β1, 
a multifunctional peptide which regulates various cell 
activities, including growth and differentiation, and 
ECM macromolecule expression and metabolization21,22. 
TGF-β1 triggers the production of fibronectin by 
fibroblasts, which by its turn triggers the synthesis of 
α-SMA that is incorporated to stress fibers. Then new 
proteins are synthesized to allow molecular adhesion 
between α-SMA myofilaments, cytoplasmic membrane, 
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and fibronectin, thus characterizing fully-differentiated 
myofibroblasts8,20.
Morpho-physiological and immunohistochemical 
aspects
Myofibroblasts are cells that physiologically secrete 
high levels of cytokines, growth factors, chemokines, 
hormones, inflammatory mediators, adhesion proteins, 
and ECM proteins2,7. Myofibroblasts are present in small 
quantities in most organs, in particular in those in which 
mechanical strength is required: the oral cavity, the skin, 
the gastrointestinal tract, the uterus, the testes, and the 
heart20,21.
Morphologically, myofibroblasts are elongated or 
stellate cells with pale eosinophilic cytoplasm and an 
even, centrally located nucleus, with minor indentations 
and small nucleoli12. Ultrastructurally, myofibroblasts are 
characterized by the presence of a contractile apparatus 
organized in the form of bundles of peripheral α-SMA 
myofilaments, analogue to the stress fibers seen on 
in-vitro cultured fibroblasts. These myofilaments are 
connected to a specialized adhesion complex located 
on the cellular surface, called fibronexus16,17,20. In these 
structures myofilaments connect to integrins, which 
then bind to fibronectin in the ECM. In functional 
terms, this contractile apparatus provides for a 
mechanotransduction system to transmit the forces 
generated by the stress fibers to the ECM17,23,24.
Similarly to active fibroblasts, the myofibroblast 
cell has well-developed rough endoplasmic reticulum 
and Golgi apparatus, as a result of intense protein 
synthesis and secretion, particularly collagen17,20. As 
in smooth muscle cells, the presence of gap junctions 
allows for adhesion and electrochemical communication 
between myofibroblasts, although they do not have an 
external lamina12,17,20,23.
Marker α-SMA has been described as the 
most relevant molecule in identifying differentiated 
myofibroblasts4,15, though it cannot tell them from smooth 
muscle cells15,17. Myofibroblasts are usually negative for 
antigens present in smooth muscle cells, such as heavy 
myosin chains, caldesmon, and desmin16,18,20. However, 
studies have shown that myofibroblasts, particularly in 
more advanced stages of differentiation, may express 
antigens seen in smooth muscle cells23,25, revealing that 
the pattern of expression of these proteins may vary 
depending on the site and nature of the pathological 
process. Typically, myofibroblasts are negative for 
cytokeratins (epithelial cell markers), CD68 (monocyte/
macrophage marker), CD31 (endothelial cell marker), 
and CD344,12,26.
In the 1990s, smoothelin - a protein associated 
with the contractile apparatus - was considered a marker 
for smooth muscle cell late differentiation, whose 
expression was not seen in myofibroblasts27,28. Further 
research found that lung fibroblasts treated with TGF-β1 
could express smoothelin29. More recently, the 4Ig 
isoform of protein palladin in stress fibers was proposed 
as a new marker for myofibroblast differentiation30. 
However, a Western blotting protocol using antibodies 
against various forms of palladin protein found 
expression of this isoform in smooth muscle cells31. 
According to Hinz et al.15, no cytoskeletal proteins have 
been found to differentiate myofibroblasts from smooth 
muscle cells yet.
Myofibroblasts and oral squamous cell carcinoma
Myofibroblasts have been identified as important 
components in the stroma of various solid malignant 
tumors, such as breast carcinoma, hepatocellular 
carcinoma, and melanoma2,4,11. Nonetheless, few papers 
have looked into the presence of myofibroblasts in oral 
SCC and the possible impact myofibroblasts have on 
the biological behavior of these neoplasms. Most of 
these papers were published only within the last five 
years3,5,13,32-36.
Lewis et al.6 studied in vitro cell lines of oral 
SCC and normal primary oral fibroblasts and verified 
that neoplastic cells - through TGF-β1 secretion - can 
induce fibroblast differentiation into myofibroblasts. 
The authors also observed that myofibroblasts secreted 
greater quantities of HGF when compared to primary 
fibroblasts, and that HGF promoted oral cancer cell 
invasion into a Matrigel matrix. According to the 
authors, these findings imply the existence of a double 
paracrine mechanism between oral cancer cells and 
myofibroblasts.
Kellermann et al.8 used an experimental model 
similar to the one employed by Lewis et al.6, and found 
supporting evidence for the important role of oral 
cancer cells in the differentiation process of normal 
primary fibroblasts into myofibroblasts through TGF-β1 
secretion. Additionally, the authors noticed that the 
treatment of oral cancer cell lines with myofibroblast 
conditioned medium led to significant increases in tumor 
cell proliferation rates. According to Kellermann et al.8, 
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the results reported in their study revealed the existence 
of mutual paracrine effects between oral cancer cells 
and normal oral fibroblasts, characterized by the 
triggering of transdifferentiation of the latter cell types 
into myofibroblasts and the modulation of malignant 
neoplastic cell proliferation.
Studies done using animal models also revealed 
evidence suggesting malignant epithelial cells have a 
special role in the appearance of myofibroblasts in oral 
cancer patients. Vered et al.37 carried out an experimental 
study on carcinogenesis with 4-Nitroquinoline 1-oxide 
(4NQO) in the tongue mucosa of Wistar rats and 
observed that in areas of normal, hyperkeratotic/
hyperplastic, and dysplastic epithelium, myofibroblasts 
were scarce or completely absent in the underlying 
connective tissue. However, in areas of superficial basal 
cell or invasive carcinoma, a significant increase on the 
number of myofibroblasts was seen, with close proximity 
between these cell types and malignant neoplastic cells. 
According to the authors, these findings suggested 
the occurrence of significant epithelial-mesenchymal 
interactions simultaneously to malignant transformation 
or possible transdifferentiation of malignant epithelial 
cells into myofibroblasts during oral carcinogenesis.
In addition to the findings reported previously, 
Vered et al.35 observed, in an experimental study using 
4NQO in the lingual mucosa of rats, that the oral 
carcinomas of desalivated rats had significantly fewer 
myofibroblasts when compared to carcinomas of rats 
without salivary flow disorder. According to the authors, 
the presence of a significant number of myofibroblasts in 
oral SCC appears not to depend only on factors secreted 
by malignant epithelial neoplastic cells, but also on the 
participation of chemical mediators found in saliva, 
particularly TGF-β.
Kellermann et al.3 used immunohistochemistry to 
look into the presence of myofibroblasts in tongue SCC, 
oral epithelial dysplasia, and normal mucosa specimens. 
Unlike in normal oral mucosa and oral epithelial 
dysplasia specimens, myofibroblasts were observed only 
in the stroma of carcinomas, particularly in the tumor 
invasion front. Additionally, lower survival rates were 
seen in patients whose tumors had abundant amounts 
of myofibroblasts in the tumor invasion front. Similar 
results were obtained in a study done by Kawashiri 
et al.33 on SCCs of various regions of the oral cavity. 
According to Kellermann et al.3, analyzing the number 
of myofibroblasts in tongue SCC may be useful in 
determining patient prognosis.
Vered et al.35 used immunohistochemistry to 
analyze the presence of myofibroblasts in tongue 
SCC specimens and observed higher tumor incidence 
with greater scores of myofibroblasts in patients aged 
under 60 years. The authors also saw that the 5-year 
disease-free survival rates of patients whose tumors 
had more myofibroblasts were lower (37.6% vs. 82.3%). 
Additionally, the percentage of survivors five years 
after diagnosis was significantly lower in the group 
with tumors with more myofibroblasts (61.2%) when 
compared to the group with fewer myofibroblasts 
(90.6%). Multivariate regression analysis revealed that 
abundance of myofibroblasts in the tumor stroma had 
an independent adverse impact on local recurrence 
rates. According to Vered et al.35, abundance of 
myofibroblasts in tongue SCC stroma increases the 
risk of local recurrence, particularly in patients under 
60 years of age.
DISCUSSION
Although in the past the stroma was considered 
as a support tissue for neoplastic cells, the results 
obtained in numerous scientific investigations indicate 
that it can regulate the processes of tumor invasion 
and metastasis2,4,5. Despite the diversity of cell types 
in the tumor stroma - blood and lymphatic endothelial 
cells, inflammatory cells, immune system cells - studied 
have suggested that myofibroblasts are among the 
main cell types involved in the promotion of malignant 
phenotypes1-5,10.
Although few in number, the studies done on 
oral SCC suggest myofibroblasts have an important 
role in the process of tumor invasion, in addition to 
correlating with local disease recurrence and reduced 
patient survival3,5,6,33-36. The molecular mechanism by 
which myofibroblasts impact the biological behavior of 
oral SCC is yet to be fully understood, but it may involve 
the modulation of the expression of various growth 
factors, cytokines, ECM components, and proteolytic 
enzymes, particularly matrix metalloproteinases (MMPs), 
as reported in studies concerning other malignant 
neoplasms1,5,8.
Given their ability to synthesize and secrete 
different growth factors such as HGF, PDGF, KGF, 
and granulocyte-macrophage colony-stimulating 
factor (GM-CSF)1,2,38, research has indicated that 
myofibroblasts play an important role in neoplastic cell 
proliferation10,39. Despite this statement, Lewis et al.6 
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observed that oral cancer cells cultured in a fibroblast 
conditioned medium had similar cell proliferation rates 
to specimens cultured in myofibroblast conditioned 
medium. By their turn, Kellermann et al.8 reported 
significant increases in cell proliferation rates in oral 
cancer cells cultured in myofibroblast conditioned 
medium. The effect myofibroblasts appear to have on 
oral cancer cell proliferation rates was further supported 
by Sobral et al.5. Additionally, these authors identified 
that the effects myofibroblasts exert upon oral cancer 
cell proliferation rates arise from the secretion of activin 
A, a protein from the TGF-β family.
Research has indicated that myofibroblasts may 
foster the migration of neoplastic cells17,40, probably 
by secreting proteases that degrade components of 
the extracellular matrix such as MMPs -2, -3 and -94,41, 
urokinase-type plasminogen activator2,39, and fibroblast 
activation protein40. Along the same lines, Sobral et al.5 
found, on an in vitro study, that myofibroblasts triggered 
the invasion of oral cancer cells in a Matrigel matrix, 
an event accompanied by increased metalloproteinase 
synthesis in tumor cells, particularly MMPs -1, -2, -9, 
and -13. Additionally, the authors observed a significant 
in vivo correlation through zymography between the 
presence of myofibroblasts and enzymatic activity 
of MMPs -2 and -9 in samples of oral cancer cells. 
Other studies regarding oral SCC have yet revealed 
that myofibroblasts promote tumor invasion by 
secreting chemokines42 and synthesizing specific ECM 
components such as some laminin isoforms43.
Despite the various mechanisms presented 
previously and the research suggesting an important role 
for myofibroblasts in oral SCC invasion and correlating 
the presence of myofibroblasts to local disease 
recurrence and diminished patient survival3,5,6,33-36, 
immunohistochemistry findings revealed that significant 
percentages of oral SCC cases have low myofibroblast 
counts or are negative for this cell type.
Kellermann et al.8 reported 39.48% (n = 15) of 
oral SCC cases categorized as negative for stromal 
myofibroblasts. Additionally, 11 (47.82%) of the 23 oral 
SCC patients positive for myofibroblasts had low counts 
of this cell type. Nonetheless, the authors observed 
a significant correlation between high myofibroblast 
counts in the tumor stroma, regional node involvement, 
advanced clinical staging, and regional (nodal) 
recurrence. On another study, De-Assis et al.9 described 
high myofibroblast counts in 15 (36.58%) of 41 oral SCC 
patients tested through immunohistochemistry, most 
of whom had high histological grades of malignant 
disease9. Altogether, the findings in these studies 
showed that myofibroblasts were not present in all 
cases of oral SCC, in addition to suggesting that stromal 
myofibroblast count could aid in the identification of 
biologically more aggressive neoplasms.
In addition to not being abundantly present in all 
cases of oral SCC, several studies have indicated that 
myofibroblasts were involved only in later-stage oral 
cancers. Leukoplakic lesions with varying degrees of 
epithelial dysplasia did not present myofibroblasts in the 
lamina propria, as the appearance of significant amounts 
of myofibroblasts was associated with invasion of the 
underlying connective tissue3,9,13. According to Etemad-
Moghadam et al.13, the appearance of myofibroblasts in 
oral SCC may be related to the effects carcinomatous 
epithelium exerts upon the neighboring stroma.
CONCLUSION
Myofibroblasts are a relevant component in 
the stroma of oral cancer cells, although they are not 
present in all oral SCC cases. Although few in number, 
in vitro studies indicate that myofibroblasts are involved 
in the contractile function in the invasion process 
of oral SCC, probably as a result of the modulation 
of the expression of growth factors, cytokines, ECM 
components, and proteolytic enzymes. Additionally, 
clinical, pathology, and immunohistochemistry tests 
have correlated the presence of high myofibroblast 
counts in oral cancer cell stroma with local disease 
recurrence and reduced patient survival. Despite the 
importance of these findings, the limited number of 
studies on the topic calls for additional research so that 
the molecular mechanisms by which myofibroblasts 
impact the biological behavior of oral SCC are further 
clarified.
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